Aethlon Medical to Initiate Clinical Trial for Blood Purification Device

New York, June 6, 2024 - PRISM MarketView - Medical Therapeutics company, Aethlon Medical (Nasdaq: AEMD) is topping the PRISM MarketView Medical Devices Index during the day on Thursday. The company provided an update this week on its planned Phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. Aethlon’s share price rose nearly 30% during the day on Thursday, reaching $0.55.

Aethlon’s Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation.

Aethlon is awaiting Ethics Committee approvals and will finalize the design of its clinical trial agreements. Once these agreements are completed, hospitals can begin recruiting patients for the trials.

In May 2024, Aethlon announced the pricing of a $4.7 million public offering of up to 8,100,000 shares of common stock, at a combined public offering price of $0.58 per share.

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.

PRISM MarketView
info@prismmarketview.com
646-863-6341